Levosimendan for post-partum cardiomyopathy.

"Cabergoline, Levosimendan and Iabp: Treatment of Peripartum Cardiomyopathy"

PeriPartum CardioMyopathy (PPCM) is a rare but potentially devastating cause of heart failure. We reported the case of a 31-year-old female who developed cardiogenic shock twelve hours post-delivery secondary to PPCM that was successfully treated with combined supportive care, including the cabergoline, levosimendan and IABP.

Diabetic cardiomyopathy and post-infarct ventricular remodelling : Effects of levosimendan in a rodent model of type II diabetes

Can the outcome of post partum cardiomyopathy be predicted using late gadolinium enhancement CMR?

Background Post partum cardiomyopathy (PPCM) can occur between the last trimester of pregnancy or within 5 months post partum, in the absence of any history of heart disease. Although rare, it may become unresponsive to medical treatment and can in such cases, require mechanical support or even a heart transplant. Predicting its evolution is unfortunately not possible. Late gadolinium enhanceme...

Reversible dilated cardiomyopathy associated with post-partum thyrotoxic storm.

The following case of a young mother presenting with post-partum pulmonary oedema, highlights a singular and life-threatening complication of a common condition (thyrotoxicosis). While thyrotoxic heart disease is well described, thyrotoxic storm in the post-partum period associated with dilated cardiomyopathy, congestive cardiac failure and ventricular fibrillation is exceptional.

Reversion of Severe Mitral Insufficiency in Peripartum Cardiomyopathy Using Levosimendan

Idiopathic peripartum cardiomyopathy presenting with heart failure is a true diagnostic and treatment challenge. Goal oriented clinical management aims at the relapse of left ventricular systolic dysfunction. A 35-year-old patient on her 12th day post-delivery presents progressive signs of heart failure. Transthoracic echocardiography showed severe mitral insufficiency, mild left ventricular dy...